secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001753926-25-001766
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Q3: ZELSUVMI launch generates $7.1M net revenue, net loss $16.2M
------------------------------------------------------------------------

- Net product revenue of $7.1M from ZELSUVMI in first commercial quarter (Q3 ended Sep 30, 2025).
- 2,716 units prescribed by 1,169 unique prescribers; October alone saw 2,189 units prescribed.
- Net loss of $16.2M ($5.30 per basic/diluted share); as-converted net loss of $1.83/share.
- Cash of $14.2M at Sep 30, 2025; closed $18M convertible notes financing in Nov 2025.
- Completed acquisition of XEPI (FDA-approved impetigo treatment) in Nov 2025, adding complementary dermatology product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001766/0001753926-25-001766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001766/g085015_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer